Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.60 |
| ▸ | ERBB4 | Q15303 | 8/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15520293 | 0.82 | EGFR (0.60) | EGFRERBB2ABCG2MEN1KMT2A | |
| SCHEMBL24167219 | 0.80 | EGFR (0.65) | EGFRERBB2ERBB4ABCG2MEN1 | |
| SCHEMBL28389700 | 0.77 | EGFR (0.61) | EGFRERBB2ERBB4 | |
| SCHEMBL29350915 | 0.76 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL29350449 | 0.76 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL412104 | 0.76 | EGFR (1.00) | EGFRERBB2ERBB4ABCG2 | |
| SCHEMBL27748903 | 0.76 | EGFR (0.64) | EGFRERBB2ERBB4BTK | |
| SCHEMBL7243449 | 0.75 | EGFR (0.70) | EGFRERBB2ERBB4ABCG2PIK3CD | |
| SCHEMBL7242457 | 0.75 | EGFR (0.67) | EGFRERBB2ERBB4ABCG2MEN1 | |
| SCHEMBL7122157 | 0.74 | EGFR (0.50) | EGFRERBB2ERBB4ABCG2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000039-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | WYETH CORP (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-0980244-B1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH CORP (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6323209-B1 | QUINAZOLINE COMPOUNDS IN THE TREATMENT AND INHIBITION OF COLONIC POLYPS. | AMERICAN CYANAMID COMPANY | 2001-11-27 | — | — | US | disclosed |
| US-6251912-B1 | Substituted quinazoline derivatives | AMERICAN CYANAMID COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-1039910-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | American Cyanamid Company (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1000039-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | American Cyanamid Company (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999024037-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
| WO-1999009016-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| EP-0787722-A1 | Substituted quinazoline derivatives | American Cyanamid Company (US) | 1997-08-06 | — | — | EP | disclosed |